NeoGenomics Laboratories, Inc. (NEO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$17.38-0.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · NEO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 222.0% |
| Our one-year growth estimate | diamond | 11.5% |
Growth built into the price is above our model estimate.
The price assumes 210.5 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 32 industry peers
NEO — government funding
Dated 2026-07-22
Other Events. As previously disclosed, the Company voluntarily conducted an internal investigation that focused on the compliance of certain consulting and service agreements with federal healthcare laws and regulations, including those relating to fraud, waste and abuse. The Company voluntarily notified the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG-HHS”) of the internal investigation in November 2021. On July 20, 2026, the Company finalized a civil…
Why it matters: Keeping EBITDA above this level shows good cost control and growth.
Supportive ifAdjusted EBITDA was over $14 million for Q3.
Worry ifAdjusted EBITDA was below $14 million for Q3.
Why it matters: Higher adjusted EBITDA means better profits. It helps management focus on making more money.
Supportive ifAdjusted EBITDA for 2026 is more than $57 million.
Worry ifAdjusted EBITDA for 2026 is less than $55 million.
Why it matters: Her experience in AI and cancer care could drive strategic changes. This may enhance NeoGenomics' product offerings.
Supportive ifBoard decisions reflect her insights, leading to new product launches or partnerships within six months.
Worry ifHer appointment does not bring any big changes or new plans during this time.
Why it matters: Approval would improve NeoGenomics' products and help them make more money.
Supportive ifMolDx approves the RaDaR ST for a new indication.
Worry ifMolDx denies the RaDaR ST submission or delays the decision.
Why it matters: Strong growth in clinical services shows demand for NeoGenomics' testing solutions. It reflects ongoing success in their growth strategy.
Supportive ifQ3 clinical services revenue growth above 14% year over year.
Worry ifClinical services revenue growth falls below 10% year over year.
Why it matters: Confirming guidance will show if NeoGenomics can sustain its growth momentum after a strong Q1.
Supportive ifQ2 revenue guidance aligns with or exceeds the revised full-year guidance of $797-$803 million.
Worry ifQ2 revenue guidance is lowered or falls below the previous guidance range.
Why it matters: The success of this assay launch could drive significant revenue growth in a large addressable market.
Supportive ifMore use of the RaDaR ST test will lead to clinical revenue growth over 14% each year.
Worry ifLow use rates or bad feedback from the market about the RaDaR ST test.
Why it matters: Her experience in AI and data insights could drive new strategies for NeoGenomics.
Supportive ifManagement shares new plans that use AI insights in cancer care.
Worry ifNo new plans are shared within six months of her start.
Why it matters: A smaller net loss shows better cost management. It also means more efficient operations.
Supportive ifNet loss decreases further from $17 million in Q1 2026.
Worry ifNet loss increases or remains stagnant compared to Q1 2026.
Why it matters: Finishing this offering could make the company's finances stronger. It may help growth plans.
Supportive ifThe $275 million convertible notes offering is done. The market liked it.
Worry ifFailure to complete the offering or negative market reaction to the notes.
Why it matters: New products are important for revenue growth and keeping a strong market position.
Supportive ifManagement shares news of a successful launch of new cancer tests or key partnerships.
Worry ifNo new product launches or partnerships are announced in the next quarter.
Why it matters: Hitting this revenue target shows strong growth. It also supports management's plan.
Supportive ifQ2 2026 revenue reported at or above $200 million.
Worry ifQ2 2026 revenue reported below $190 million.
Why it matters: Approval would show that NeoGenomics has good testing solutions. It could help make more money.
Supportive ifMedicare will pay for RaDaR ST.
Worry ifReimbursement for RaDaR ST is denied or delayed.
Why it matters: The offering might change the stock price. It could also affect how investors feel due to dilution worries.
Watch forThe stock price stays the same or goes up after the convertible senior notes offering.
Also watch forThe stock price drops a lot after the convertible senior notes offering.
Why it matters: Higher operating income is important. It helps the company make money and gain investor trust.
Supportive ifOperating income gets much better from the current loss of $18 million.
Worry ifOperating income stays negative or gets worse in the next quarters.
Why it matters: Better operating income means the company is losing less money. This may help investors feel good.
Supportive ifQ2 operating income improves compared to last year. It is getting closer to breaking even.
Worry ifQ2 operating income gets worse or stays negative.
Why it matters: Changes in leadership can change company plans and results. This may affect how investors feel.
Watch forNew leadership brings a clear strategic plan that improves performance.
Also watch forLeadership change leads to confusion or lack of direction.
Why it matters: How the market reacts to the offering shows investor trust and the health of finances.
Watch forNeoGenomics' stock price goes up a lot after the offering.
Also watch forNeoGenomics' stock price goes down a lot after the offering.
Why it matters: Higher gross profit means the company makes more money. This can bring in more investors.
Supportive ifQ2 gross profit increases year over year, exceeding $80.9M.
Worry ifQ2 gross profit declines or stays below $80.9M.
Why it matters: Growth above 10% shows management wants to increase revenue. It shows the company can keep going.
Supportive ifQ3 revenue growth was over 10% compared to last year.
Worry ifQ3 revenue growth was under 10% compared to last year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$232 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $475 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,561 loss on $10,000 · 45.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.